- Developments in the Frontiers of Diagnosis and Treatment for Bipolar Disorder 
and Schizophrenia Receive Extensive Attention

The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma 
Group recently took place in Nanjing. Dozens of psychiatrists and experts from 
8 countries and regions including China, Korea, Malaysia, and Thailand gathered 
at the conference to hold discussions on the frontiers of psychiatry as well as 
the future direction for diagnosis and treatment strategies.

The presidium of the conference consisted of Professor Fang Yiru, Vice Chairman 
of the Chinese Society of Psychiatry under the Chinese Medical Association, and 
Director of the Shanghai Mental Health Center's Clinical Center, Dr. Lo Tak 
Lam, Professor of Psychiatry from the University of Hong Kong, and Chairman of 
the Mental Health Association of Hong Kong, and Professor Su Dongping, 
Professor of Psychiatry from the National Yang-Ming University in Taiwan.

Focusing on bipolar disorder and schizophrenia, the attendees shared their 
insights on the academic developments in the frontiers, the latest schemes for 
diagnosis and treatment in clinical practice, as well as clinical case studies, 
covering the developments and challenges in various stages including the 
diagnosis, treatment and prognosis of mental illness.

Photo - https://photos.prnasia.com/prnh/20190902/2567397-1
(Experts from Asia Pacific holding discussions on academic and clinical 
developments in psychiatry)

The Asia Pacific region faces a heavy burden in mental illness, and the low 
diagnosis rate remains a major challenge for countries in the region

According to the Mental Health Integration Index Results for Asia-Pacific 
published by The Economist Intelligence Unit in 2016, mental diseases accounted 
for 9.3% of the overall disease burden in the Asia Pacific region, and mental 
health is the second largest contributor to years lost due to disability (YLDs) 
in this region. It is estimated that mental diseases will cause the 
productivity of China and India to decrease by over $9 trillion and $2 trillion 
respectively from 2012 to 2030. In Australia and New Zealand, mental illness 
currently knocks 3.5% and 5% respectively off GDP. In Korea where suicide is an 
extremely severe problem, the total economic loss caused by suicides in 2012 
alone was up to $5.9 billion, slightly lower than 0.5% of the country's GDP for 
that year.

Despite the heavy burden caused by mental diseases to the public, the visit 
rate and diagnosis rate of mental illness have been low in Asia Pacific. Across 
the region, patients that have never received any treatment are over 50% and 
90% in developed countries and developing countries respectively. Problems such 
as people's discrimination against/ misunderstanding of mental illness, the 
lack of professional psychiatrists, and the uneven distribution of medical 
resources vary from one country to another in Asia Pacific, causing a low 
diagnosis rate. It's urgent to drive team building and increase public 
awareness throughout this region.

Asia Pacific experts hold heated discussions in the academic frontiers and on 
future strategies and directions for diagnosis and treatment

During the conference, psychiatrists from Asia Pacific countries and regions 
shared their insights on the academic frontiers of mental health. Their 
discussions touched a wide range of topics about schizophrenia and bipolar 
disorder, including therapeutic targets, progress of clinical trials, and 
potential breakthrough therapies. They also learned from each other with 
respect to diagnosis and treatment experiences as well as patient types by 
sharing case studies. Meanwhile, they also discussed sustained release dosage 
forms. According to them, how to improve patient compliance and further improve 
prognosis through more convenient and more friendly ways to deliver drugs is 
also one of the hot topics in clinical studies today. 

Luye Pharma drives CNS studies to serve patients around the world

This was the first time for Luye Pharma to host the Asia Pacific Psychiatric 
Conference. The company's commitment to this area was proven by the influence 
of the conference and the depth of the discussions. Zhou Jun, Vice President of 
International Market at Luye Pharma, said at the conference: "I am very excited 
to see that this Psychiatric Conference has received attention from and been 
participated by so many physicians and scholars in the Asia Pacific region. 
Luye Pharma hopes to continue to organize more academic exchanges and work with 
central nervous system experts and scholars to drive progress of clinical 
diagnosis and treatment in this field; we also hope to provide patients with 
more innovative drugs to help alleviate their disease burden and improve their 
quality of life."

The central nervous system is one of the core strategic areas for Luye Pharma. 
Multiple drugs in development have entered the late clinical stage, and a 
series of products have already been launched, including Seroquel and Seroquel 
XR, Rivastigmine transdermal patches, Fentanyl patches, and Buprenorphine 
patches, covering more than 80 countries and regions in the world. Meanwhile, 
Luye Pharma has 7 major production bases and over 30 production lines around 
the world, and has established the Good Manufacturing Practices (GMP) quality 
management and control system, to help global patients benefit from its 
research findings. 

SOURCE  Luye Pharma

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=343945

   Caption: Experts from Asia Pacific holding discussions on academic and 
clinical developments in psychiatry